ALK-Abello

07.06.2008 – 12:02
GRAZAX(R) Demonstrates Significant Reductions on Asthma Symptoms in Children
Barcelona (ots/PRNewswire) - - In Addition to Effects on Allergic Rhinitis (Hayfever), GRAZAX(R) Demonstrated Significant Reductions in Asthma Symptoms in Children Aged 5 to 16 Years Old ALK-Abelló today presented successful results from a new clinical trial, GT-12, designed to measure the impact of GRAZAX(R) on allergic rhinitis and allergic asthma. GT-12 ...
mehr
17.03.2008 – 11:06
ALK-Abelló, the Makers of GRAZAX(R), Present Successful Phase III Clinical Study Results with Children
Horsholm, Denmark (ots/PRNewswire) - - Results Show Highly Significant Effect on Rhinoconjunctivitis (Hay Fever) and Asthma Symptoms in Children from age 5 to 16 Years-old ALK-Abelló yesterday presented successful Phase III clinical study results with GRAZAX(R) in children at the American Academy ...
mehr